Ohr Pharmaceutical reports net loss for fiscal year

Ohr Pharmaceutical reported a net loss of $23.8 million, or $0.53 per share, for its fiscal year that ended Sept. 30 compared with a net loss of $25.8 million, or $0.82 per share, a year ago, according to a press release.
Operating expenses included $5.3 million in general and administrative expenses, $17.4 million in research and development costs, and $1.2 million in depreciation and amortization compared with last year’s expenses of $7.7 million in general and administrative costs, $16.5 million in research and development, and $1.2 million in depreciation and (Read more...)

Full Story →